These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24083342)

  • 1. Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study.
    Tielemans MM; van Oijen MG
    BMC Gastroenterol; 2013 Oct; 13():144. PubMed ID: 24083342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument.
    Tielemans MM; Jansen JB; van Oijen MG
    Interact J Med Res; 2012 Sep; 1(2):e7. PubMed ID: 23611985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].
    Labenz J; Labenz G; Stephan D; Willeke F;
    MMW Fortschr Med; 2016 May; 158 Suppl 4():7-11. PubMed ID: 27221555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11).
    Lacy BE; Chehade R; Crowell MD
    Am J Gastroenterol; 2011 Sep; 106(9):1604-11. PubMed ID: 21691342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon.
    Savarino EV; Tolone S; Bartolo O; de Cassan C; Caccaro R; Galeazzi F; Nicoletti L; Salvador R; Martinato M; Costantini M; Savarino V
    Aliment Pharmacol Ther; 2016 Sep; 44(5):522-30. PubMed ID: 27373195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
    Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
    Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms, the GerdQ score and patients' characteristics do not predict gastroesophageal reflux disease in patients with proton-pump-inhibitor-refractory reflux symptoms-results from a large prospective database.
    Labenz J; Menzel M; Hirsch O; Müller M; Labenz C; Adarkwah CC
    PeerJ; 2023; 11():e14802. PubMed ID: 36846452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic value of GerdQ in subjects with atypical symptoms of gastro-esophageal reflux disease.
    Norder Grusell E; Mjörnheim AC; Finizia C; Ruth M; Bergquist H
    Scand J Gastroenterol; 2018; 53(10-11):1165-1170. PubMed ID: 30353750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
    Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
    J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of the Gastroesophageal Reflux Disease Questionnaire (GerdQ) in predicting the proton pump inhibitor response in coronary artery disease patients with gastroesophageal reflux-related chest pain.
    He S; Liu Y; Chen Y; Tang Y; Xu J; Tang C
    Dis Esophagus; 2016 May; 29(4):367-76. PubMed ID: 25721424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores.
    Yamamichi N; Mochizuki S; Asada-Hirayama I; Mikami-Matsuda R; Shimamoto T; Konno-Shimizu M; Takahashi Y; Takeuchi C; Niimi K; Ono S; Kodashima S; Minatsuki C; Fujishiro M; Mitsushima T; Koike K
    BMC Med; 2012 May; 10():45. PubMed ID: 22554226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
    Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting.
    Zschau NB; Andrews JM; Holloway RH; Schoeman MN; Lange K; Tam WC; Holtmann GJ
    World J Gastroenterol; 2013 Apr; 19(16):2514-20. PubMed ID: 23674853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.
    Bruley des Varannes S; Löfman HG; Karlsson M; Wahlqvist P; Ruth M; Furstnau ML; Despiégel N; Stålhammar NO
    BMC Gastroenterol; 2013 Feb; 13():39. PubMed ID: 23448382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the GerdQ questionnaire for the diagnosis of gastro-oesophageal reflux disease.
    Jonasson C; Wernersson B; Hoff DA; Hatlebakk JG
    Aliment Pharmacol Ther; 2013 Mar; 37(5):564-72. PubMed ID: 23289763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
    Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
    Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.